Form D · Biotechnology

Kallyope, Inc.

New York, NY · CIK 0001655846

Offering snapshot reported Oct 27, 2016 · SEC filing

Reported sold
$28.1M
Offering amount: $44.1M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 30, 2015
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$14M$28.1MOct 15, 2015: $12,050,000.00Oct 15, 2015Oct 27, 2016: $28,050,000.00Oct 27, 2016

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$12,050,000 → $28,050,000
  • Reported investors8 → 9

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 27, 2016Amendment$28,050,000$16,000,000vs Oct 15, 20159SEC filing
Oct 15, 2015Initial$12,050,000No comparison8SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-249469

Source: Form D, filed Oct 27, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Kenneth Clark Executive
Adam Goulburn Director, Executive
Tim Kutzkey Director
Tom Maniatis Director
Terry Mc Guire Director
Michael O'donnell Executive
William Rieflin Director
Nancy Thornberry Director, Executive
Joshua Wolfe Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
430 East 29 Th Street 10 Th Floor
New York, NY, 10016